TSHA-102

TSHA-102 is an experimental gene therapy developed by Taysha Gene Therapies for Rett syndrome, delivered via adeno-associated virus serotype 9.^[1]^[2]^[3]^[4]^[5]

References[edit]

^ Philippidis, Alex (1 January 2022). "StockWatch: Astellas Hones Gene Therapy Focus with Taysha Stake: Tricida shares crater after failed Phase III trial; Vaxcyte bolsters challenge to Pfizer with clinical success; ESSA triples after acing prostate cancer study". GEN Edge. 4 (1): 809–815. doi:10.1089/genedge.4.1.137. S2CID 253331384.
^ Philippidis, Alex (1 January 2023). "StockWatch: Seven Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts: Gene therapy developer says call for randomized placebo-controlled trial is 'unfeasible'; Evelo falls on clinical miss; HillStream jumps on Dana-Farber deal". GEN Edge. 5 (1): 128–132. doi:10.1089/genedge.5.1.28. S2CID 257006849.
^ Philippidis, Alex (1 October 2020). "Sarepta Duchenne Muscular Dystrophy Candidate Faces U.S. Food and Drug Administration Assay Request, Patent Suit". Human Gene Therapy. 31 (19–20): 1031–1033. doi:10.1089/hum.2020.29137.bfs. PMID 33074027. S2CID 224780854.
^ Philippidis, Alex (1 January 2023). "Taysha Faces Stock Delisting, Scraps $75M Durham Manufacturing Facility: Company aims to preserve capital while anticipating second-half clinical milestones for key programs, with Q1 results expected Thursday". GEN Edge. 5 (1): 362–367. doi:10.1089/genedge.5.1.70. S2CID 258737047.
^ Philippidis, Alex (1 January 2023). "StockWatch: Illumina Results Leave Investors, Analysts Anxious: Taysha zooms on $150M PIPE financing; Alaunos plunges on job cuts; Design nosedives on patient 'reactions'; Phase IIb trial failure sinks Galecto; Zynerba quadruples on up-to-$200M buyout by Harmony". GEN Edge. 5 (1): 549–556. doi:10.1089/genedge.5.1.106. S2CID 265960414.

[1] Philippidis, Alex (1 January 2022). "StockWatch: Astellas Hones Gene Therapy Focus with Taysha Stake: Tricida shares crater after failed Phase III trial; Vaxcyte bolsters challenge to Pfizer with clinical success; ESSA triples after acing prostate cancer study". GEN Edge. 4 (1): 809–815. doi:10.1089/genedge.4.1.137. S2CID 253331384.

[2] Philippidis, Alex (1 January 2023). "StockWatch: Seven Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts: Gene therapy developer says call for randomized placebo-controlled trial is 'unfeasible'; Evelo falls on clinical miss; HillStream jumps on Dana-Farber deal". GEN Edge. 5 (1): 128–132. doi:10.1089/genedge.5.1.28. S2CID 257006849.

[3] Philippidis, Alex (1 October 2020). "Sarepta Duchenne Muscular Dystrophy Candidate Faces U.S. Food and Drug Administration Assay Request, Patent Suit". Human Gene Therapy. 31 (19–20): 1031–1033. doi:10.1089/hum.2020.29137.bfs. PMID 33074027. S2CID 224780854.

[4] Philippidis, Alex (1 January 2023). "Taysha Faces Stock Delisting, Scraps $75M Durham Manufacturing Facility: Company aims to preserve capital while anticipating second-half clinical milestones for key programs, with Q1 results expected Thursday". GEN Edge. 5 (1): 362–367. doi:10.1089/genedge.5.1.70. S2CID 258737047.

[5] Philippidis, Alex (1 January 2023). "StockWatch: Illumina Results Leave Investors, Analysts Anxious: Taysha zooms on $150M PIPE financing; Alaunos plunges on job cuts; Design nosedives on patient 'reactions'; Phase IIb trial failure sinks Galecto; Zynerba quadruples on up-to-$200M buyout by Harmony". GEN Edge. 5 (1): 549–556. doi:10.1089/genedge.5.1.106. S2CID 265960414.

[1]

[2]

[3]

[4]

[5]